April 20, 2012
Partner
WASHINGTON, DC - On April 20, 2012, a two-week trial was held on the issue of whether plaintiff Alzheimer’s Institute of America, Inc. had standing to bring a patent infringement action against Avid Radiopharmaceuticals, Inc., a subsidiary of Eli Lilly and Company. The jury in the U.S. District Court for the Eastern District of Pennsylvania found for Avid and Penn. Specifically, the jury found that the academic institution where the alleged sole inventor was employed had not waived its rights in the invention, that the inventor listed on the issued patents was not the sole inventor, and that John Hardy was a co-inventor.
With more than 375 intellectual property lawyers, Finnegan is one of the largest IP law firms in the world. From offices in Washington, DC; Atlanta, Georgia; Cambridge, Massachusetts; Palo Alto, California; Reston, Virginia; Brussels, Belgium; Shanghai, China; Taipei, Taiwan; and Tokyo, Japan, the firm practices all aspects of patent, trademark, copyright, and trade secret law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. ###
Press Release
October 6, 2026
Award/Ranking
Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027
September 24, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Commentary
Pepsi's U.S. Trademark Dispute Could Reshape Brand Choices, Lawsuit Strategy, Lawyers Say
September 17, 2026
Award/Ranking
September 11, 2026
Media Mention
Finnegan Opens First Texas Office with ‘Two Leaders with Genuine Local Roots'
September 7, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.